CD44 and leukemia: These and ancillary observations therefore suggest that overexpression of CD44 may be considered a hallmark of leukemiagenesis and these findings incite the preclinical exploration of immunotherapeutic and CAR-T cell-targeting efficacy of CD44 in diverse experimental leukemia models [32, 82].